Adamis pharmaceuticals provides update on clinical study assessing tempol for the treatment of covid-19

Dsmb met to evaluate interim clinical and safety data and clears phase 2/3 study to continue dsmb met to evaluate interim clinical and safety data and clears phase 2/3 study to continue

ADMP Ratings Summary

ADMP Quant Ranking